Literature DB >> 31017304

Chronic inflammation during osteoarthritis is associated with an increased expression of CD161 during advanced stage.

Meenakshi Sachdeva1, Aditya Aggarwal2, Ravi Sharma3, Arpan Randhawa1, Daisy Sahni1, Justin Jacob1, Vinit Sharma1, Anjali Aggarwal1.   

Abstract

Increasing evidence suggests a role of inflammation during the pathogenesis of osteoarthritis (OA). The local and systemic inflammation was studied in 33 patients of different KL grades, grade2 (n = 11), grade3 (n = 6) and grade4 (n = 16). The levels of cytokines, adipokines and matrix metalloproteinases (MMPs) were measured in serum and synovial fluid (SF) by flow cytometry and ELISA, respectively. The frequency of T cells and CD161 expression was measured by flow cytometry. The levels of IL-1β, IL-6 and IL-10 were significantly higher in sera and SF of patients with OA as compared to healthy control's serum. Higher levels of MMP9 and leptin and lower levels of adiponectin were observed in SF as compared to serum. The MMP9 in SF and MMP13 levels in serum and SF decreased in KL grade 4 cases. In these patients, higher levels of leptin and lower levels of adiponectin were observed in SF versus patients of lower grades. There was increased infiltration of CD8+ T cells in SF of OA cases with decreased frequency in grade 4 cases. The expression of CD161 on T cells was significantly higher in SF than peripheral blood with significant upregulation in grade 4 patients. The CD161 expression had significant positive correlation with IL-17 in the serum of patients. The ROC curves of CD161 expression significantly distinguished grade 2 and grade 4 patients. Collectively, an elevated CD161 expression on T cells in circulation and synovial compartment clearly distinguished lower and higher grade patients warranting studies to assess its role as a contributing factor towards OA progression.
© 2019 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Keywords:  CD161; inflammation; osteoarthritis

Mesh:

Substances:

Year:  2019        PMID: 31017304     DOI: 10.1111/sji.12770

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  CD8+ T Cells in OA Knee Joints Are Differentiated into Subsets Depending on OA Stage and Compartment.

Authors:  Hadrian Platzer; Richard Trauth; Timo A Nees; Elena Tripel; Simone Gantz; Marcus Schiltenwolf; Babak Moradi; Nils Rosshirt
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

2.  MicroRNA Mediate Visfatin and Resistin Induction of Oxidative Stress in Human Osteoarthritic Synovial Fibroblasts Via NF-κB Pathway.

Authors:  Sara Cheleschi; Ines Gallo; Marcella Barbarino; Stefano Giannotti; Nicola Mondanelli; Antonio Giordano; Sara Tenti; Antonella Fioravanti
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

3.  Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis.

Authors:  Xiaojian Huang; Bowei Ni; Yang Xi; Xiangyu Chu; Rui Zhang; Hongbo You
Journal:  Aging (Albany NY)       Date:  2019-12-16       Impact factor: 5.682

4.  Circulating IL-10 is compromised in patients predisposed to developing and in patients with severe knee osteoarthritis.

Authors:  Tyler Barker; Victoria E Rogers; Vanessa T Henriksen; Roy H Trawick; Nathan G Momberger; G Lynn Rasmussen
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

Review 5.  Cartilage tissue engineering for obesity-induced osteoarthritis: Physiology, challenges, and future prospects.

Authors:  Antonia RuJia Sun; Anjaneyulu Udduttula; Jian Li; Yanzhi Liu; Pei-Gen Ren; Peng Zhang
Journal:  J Orthop Translat       Date:  2020-09-28       Impact factor: 5.191

6.  Synovium-Synovial Fluid Axis in Osteoarthritis Pathology: A Key Regulator of the Cartilage Degradation Process.

Authors:  Dhanashri Ingale; Priya Kulkarni; Ali Electricwala; Alpana Moghe; Sara Kamyab; Suresh Jagtap; Aare Martson; Sulev Koks; Abhay Harsulkar
Journal:  Genes (Basel)       Date:  2021-06-29       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.